Patents by Inventor Tobias Zellweger

Tobias Zellweger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
    Patent number: 9095602
    Abstract: Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: August 4, 2015
    Assignee: The University of British Columbia
    Inventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson, Tobias Zellweger
  • CHEMO- AND RADIATION-SENSITIZATION OF CANCER BY ANTISENSE TRPM-2 OLIGODEOXYNUCLEOTIDES
    Publication number: 20130143944
    Abstract: Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.
    Type: Application
    Filed: January 9, 2013
    Publication date: June 6, 2013
    Applicant: The University of British Columbia
    Inventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson, Tobias Zellweger
  • Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
    Patent number: 8361981
    Abstract: Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: January 29, 2013
    Assignee: The University of British Columbia
    Inventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson, Tobias Zellweger
  • Chemo- and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides
    Publication number: 20090258089
    Abstract: Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.
    Type: Application
    Filed: April 29, 2009
    Publication date: October 15, 2009
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Martin Gleave, Paul S. Rennie, Hideaki Miyake, Colleen Nelson, Tobias Zellweger
  • Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
    Patent number: 7569551
    Abstract: Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: August 4, 2009
    Assignee: The University of British Columbia
    Inventors: Martin Gleave, Paul S. Rennie, Hikeaki Miyake, Colleen Nelson, Tobias Zellweger
  • Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
    Publication number: 20030158130
    Abstract: Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.
    Type: Application
    Filed: September 28, 2001
    Publication date: August 21, 2003
    Inventors: Martin Gleave, Paul S. Rennie, Hikeaki Miyake, Colleen Nelson, Tobias Zellweger